We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current MCPMF market cap is 359.71M. The company's latest EPS is JPY 121.3504 and P/E is 0.08.
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Revenue | 101.8B | 103B | 110.18B | 103.26B | 102.89B |
| Operating Income | 8.81B | 12B | 14.29B | 8.51B | 5.64B |
| Net Income | 4.6B | 8.59B | 10.57B | 6.65B | 4.55B |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Assets | 157.49B | 161.79B | 163.14B | 158.83B | 158.8B |
| Total Liabilities | 36.82B | 34.82B | 34.49B | 32.06B | 30.83B |
| Total Equity | 120.67B | 126.98B | 128.65B | 126.78B | 127.97B |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Operating | 9.34B | 9.2B | 7.46B | 7.3B | -7.48B |
| Investing | -1.76B | -880M | -2.01B | -2.95B | 73M |
| Financing | -5.32B | -5.11B | -5.95B | -6.89B | -6.39B |
| Market Cap | 359.71M |
| Price to Earnings Ratio | 0.08 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0.01 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 37.47M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 0.00% |
| 52 Week High | 9.60 |
| 52 Week Low | 9.60 |
| Spread (Intraday) | 32.58 (87.37%) |
| Company Name | Mochida Pharmaceutical Company Ltd (PK) |
| Address |
1-7 yotsuya shinjuku, tokyo 160-8515 |
| Website | https://www.mochida.co.jp |
| Industry | pharmaceutical diversified (H2) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
